November 8th Options Now Available For Sarepta Therapeutics (SRPT)

Investors in Sarepta Therapeutics Inc ( SRPT) saw new options begin trading today, for the November 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SRPT options chain for the new November 8th contracts and identified one put and one call contract of particular interest.

The put contract at the $36.00 strike price has a current bid of 10 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $36.00, but will also collect the premium, putting the cost basis of the shares at $35.90 (before broker commissions). To an investor already interested in purchasing shares of SRPT, that could represent an attractive alternative to paying $44.72/share today.

Because the $36.00 strike represents an approximate 20% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 84%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.28% return on the cash commitment, or 3.49% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Below is a chart showing the trailing twelve month trading history for Sarepta Therapeutics Inc, and highlighting in green where the $36.00 strike is located relative to that history:

Loading+chart++2013+TickerTech.com

Turning to the calls side of the option chain, the call contract at the $50.00 strike price has a current bid of $1.00. If an investor was to purchase shares of SRPT stock at the current price level of $44.72/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $50.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 14.04% if the stock gets called away at the November 8th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if SRPT shares really soar, which is why looking at the trailing twelve month trading history for Sarepta Therapeutics Inc, as well as studying the business fundamentals becomes important. Below is a chart showing SRPT's trailing twelve month trading history, with the $50.00 strike highlighted in red:

Loading+chart++2013+TickerTech.com

Considering the fact that the $50.00 strike represents an approximate 12% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 67%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 2.24% boost of extra return to the investor, or 28.10% annualized, which we refer to as the YieldBoost.

START SLIDESHOW:
Top YieldBoost Calls of the S&P 500 »

The implied volatility in the put contract example is 88%, while the implied volatility in the call contract example is 71%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 250 trading day closing values as well as today's price of $44.72) to be 66%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.

null

If you liked this article you might like

With an Eye on Biotech, Here's Today's Trading Thesis

With an Eye on Biotech, Here's Today's Trading Thesis

Focused on Two Sectors

Focused on Two Sectors

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

In This Booming Stock Market, Think Like a Programmer Not a Critic

In This Booming Stock Market, Think Like a Programmer Not a Critic

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits